Hospital costs of acute pulmonary embolism.

[1]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[2]  S. Goldhaber,et al.  Patient education program for venous thromboembolism prevention in hospitalized patients. , 2012, The American journal of medicine.

[3]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[4]  S. Goldhaber,et al.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. , 2011, The New England journal of medicine.

[5]  M. Holdsworth,et al.  Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event , 2011, Thrombosis and Haemostasis.

[6]  Nathan A. Pugh,et al.  Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial , 2011, The Lancet.

[7]  J. Kline,et al.  Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). , 2011, Journal of the American College of Cardiology.

[8]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[9]  M. Prins,et al.  Safety of outpatient treatment in acute pulmonary embolism , 2010, Journal of thrombosis and haemostasis : JTH.

[10]  M. Kovacs,et al.  Ambulatory management of pulmonary embolism: a pragmatic evaluation , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  Lisa Moores,et al.  Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. , 2010, Archives of internal medicine.

[12]  E. Vicaut,et al.  Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.

[13]  M. Prins,et al.  Out of hospital treatment of acute pulmonary embolism in patients with a low NT‐proBNP level , 2010, Journal of thrombosis and haemostasis : JTH.

[14]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[15]  F. Anderson,et al.  Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. , 2009, Chest.

[16]  P. Dobesh,et al.  Economic Burden of Venous Thromboembolism in Hospitalized Patients , 2009, Pharmacotherapy.

[17]  Marilyn D Paterno,et al.  Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients , 2009, Circulation.

[18]  M. Fine,et al.  Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism , 2009, Circulation.

[19]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[20]  Bengt I Eriksson,et al.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.

[21]  M. Fine,et al.  Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: a statewide perspective. , 2008, Archives of internal medicine.

[22]  Jay Lin,et al.  Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. , 2015, Journal of managed care pharmacy : JMCP.

[23]  R. Goldberg,et al.  Venous thromboembolism in the outpatient setting. , 2007, Archives of internal medicine.

[24]  M. Bullano,et al.  Longitudinal Evaluation of Health Plan Cost per Venous Thromboembolism or Bleed Event in Patients With a Prior Venous Thromboembolism Event During Hospitalization , 2005, Journal of managed care pharmacy : JMCP.

[25]  S. Goldhaber,et al.  Electronic alerts to prevent venous thromboembolism among hospitalized patients. , 2005, The New England journal of medicine.

[26]  M. Valerio,et al.  Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  G. Wells,et al.  A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism , 2005 .

[28]  L. Elting,et al.  Outcomes and cost of deep venous thrombosis among patients with cancer. , 2004, Archives of internal medicine.

[29]  S. Goldhaber,et al.  Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. , 2003, Circulation.

[30]  J. Beer,et al.  Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients 1 , 2003, Journal of thrombosis and haemostasis : JTH.

[31]  M. Kovacs,et al.  Outpatient Treatment of Pulmonary Embolism with Dalteparin , 2000, Thrombosis and Haemostasis.